The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer.
Original Article: Leave No One Behind: Optimizing Targeted Therapies in Ovarian Cancer